Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 9/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177330 | 0.83 | IDO1 (0.45) | IDO1PDE3BPDE3AP2RY12TDO2 | |
| SCHEMBL1177647 | 0.81 | IDO1 (0.59) | IDO1TDO2PDE9AALDH1A1 | |
| SCHEMBL1176947 | 0.73 | KDM4E (0.45) | IDO1PDE3BPDE3AP2RY12NPSR1 | |
| SCHEMBL8009392 | 0.71 | PDE3B (0.45) | IDO1PDE3BPDE3AP2RY12 | |
| SCHEMBL1176944 | 0.69 | IDO1 (0.59) | IDO1TDO2ALDH1A1XDH | |
| SCHEMBL12163763 | 0.66 | ADORA1 (0.51) | NPSR1ALDH1A1 | |
| SCHEMBL12163643 | 0.65 | ADORA1 (0.47) | NPSR1ALDH1A1 | |
| SCHEMBL8032685 | 0.64 | ADORA1 (0.49) | ACMSD | |
| SCHEMBL10194179 | 0.64 | ADORA1 (0.64) | ACMSD | |
| SCHEMBL14498361 | 0.63 | IDO1 (0.51) | IDO1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009080198-A1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |